Abstract Inflammatory bowel disease (IBD), primarily presenting as ulcerative colitis or Crohn’s disease, is a chronic inflammatory condition of the gut leading to increased risk of developing colorectal cancer (CRC). IBD-induced CRC, termed colitis-associated cancer (CAC), with earlier onset and higher mortality rate than sporadic CRC, follows a flat inflammation-to-dysplasia-to-carcinoma path of tumorigenesis with a mixed immune and stromal cell-rich tumour microenvironment. Long non-coding RNAs (lncRNAs), a class of non-protein-coding RNA molecules more than 200 nucleotides long are expressed in a high tissue- and disease-specific manner and may represent promising targets for therapy. We aimed to identify a lncRNA that is dysregulated in CAC patients and can be targeted as a therapy to block the development of CAC from IBD. We have identified an endothelial cell-enriched lncRNA, provisionally named LINC-ECER, that is upregulated in both colon cancer and IBD. Knockdown of LINC-ECER and functional assays in Human Umbilical Vein Endothelial Cells (HUVECs) and lymphatic endothelial cells (HLECs) in vitro revealed that LINC-ECER is an important regulator of endothelial cell survival, growth and angiogenesis. Overall, our data proposes that LINC-ECER is a critical regulator of endothelial cell properties and can be targeted in IBD patients to specifically block angiogenesis and prevent CAC development.
Leboff et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: